What Are the Fundamentals of Novartis AG (NVS)?

By Chris Stiles • Tuesday, January 17 15:03 • Permanent Link

Join us for a quick overview of Novartis AG, a Drug Manufacturing company whose shares moved 1.6% today. Here are some facts about the stock that should help you see the bigger picture:

Novartis AG has moved 1.7% over the last year, and the S&P 500 logged a change of -12.6%
NVS has an average analyst rating of buy and is -11.28% away from its mean target price of $104.25 per share
Its trailing earnings per share (EPS) is $9.7
Novartis AG has a trailing 12 month Price to Earnings (P/E) ratio of 9.5 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $6.46 and its forward P/E ratio is 14.3
The company has a Price to Book (P/B) ratio of 3.3 in contrast to the S&P 500's average ratio of 2.95
Novartis AG is part of the Healthcare sector, which has an average P/E ratio of 13.21 and an average P/B of 4.07
NVS has reported YOY quarterly earnings growth of -41.0% and gross profit margins of 0.7%
The company has a free cash flow of $12,999,249,920.00, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.